Publications by authors named "S Resino"
Article Synopsis
- This study investigated the link between immune checkpoint proteins and liver stiffness in HIV/HCV-coinfected individuals one year after successful HCV treatment, focusing on plasma levels of these proteins and their correlation with liver stiffness measured five years later.
- 39 patients with advanced liver disease who achieved sustained virologic response (SVR) were analyzed, revealing that although liver stiffness decreased over time, it remained persistently high in 61.5% of participants five years after treatment.
- Elevated levels of immune checkpoints BTLA, PD-1, and TIM-3 were associated with this persistently high liver stiffness, indicating a potential ongoing immunological impact on liver health even after HCV eradication.
Background And Aims: In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.
Methods: We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis.
Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis.
Infect Dis Poverty
December 2024
Background: The current diagnostic strategy for hepatitis C virus (HCV) infection involves a two-step approach: antibody HCV screening followed by confirmatory nucleic acid testing. This study aimed to evaluate the diagnostic performance of the Abbott ARCHITECT HCV Ag assay in serum/plasma samples as a potential one-step alternative for diagnosing active HCV infection in people living with hepatitis B virus (PLWHB) through a systematic review and meta-analysis.
Methods: A systematic review and meta-analysis were conducted following PRISMA-DTA guidelines.
Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.
Front Pharmacol
October 2024
Article Synopsis
- * A study of 80 patients who cleared HCV infection revealed that 26% developed metabolic events and 46% had increased TyG index levels over five years of follow-up.
- * Low baseline levels of the immune checkpoint proteins BTLA and LAG-3 were linked to a higher risk of developing metabolic disorders, highlighting their potential role in patient monitoring post-treatment.
Article Synopsis
- Hepatitis C virus (HCV) microelimination focuses on detecting and treating hidden infections in vulnerable populations, particularly people experiencing homelessness (PEH) who may suffer from substance use disorders, highlighting the role of point-of-care testing and peer support in infection prevention.
- A study conducted in Madrid from 2019 to 2023 assessed active HCV infection among PEH, utilizing rapid testing methods and analyzing various risk factors, including substance use and financial instability.
- Out of 2,709 screened PEH, 13.4% tested positive for HCV antibodies, with a prevalence of 6.3% for active infection; key risk factors identified were injection drug use (IDU) and associated behaviors, leading to